urosphere

News & events

Urosphere presented two posters at ERA-EDTA congress

May 27, 2016

Urosphere presented two posters in collaboration with Solid Drug Development at the 53rd annual ERA-EDTA congress: Effect of JNK inhibitor in a rat model of renal ischemia-reperfusion injury (link) Effects of JNK inhibitor on puromycin aminonucleoside-induced nephropathy in rats (link) Please click on links next to the posters titles to see them.

Urosphere and Ambiotis sign a strategic collaboration agreement

Jan 22, 2016

Urosphere and Ambiotis another Contract Research Organization, based in Toulouse, France announce a strategic partnership to broaden and strenghten their respective activities. Under this agreement, the two companies intend to combine their skills to offer an even more integrated approach to their customers. UROSPHERE will indeed bring its expertise in building physiological and pathological animal models within the uro-genital, gastro-intestinal and oncological areas while Ambiotis will offer...

UROSPHERE ANNOUNCES ISO 9001 CERTIFICATION.

Jun 30, 2015

Urosphere is pleased to announce another step in its commitment to the highest quality standards. Urosphere obtained the certification of its Quality Management System (QMS) ISO 9001: 2008 provided by Lloyd's Register Quality Assurance (LRQA), a world’s leading provider of certifications.  “Today, we become the first CRO specialized in preclinical pharmacology in the field of urogenital pathologies. We provide to our customers an internationally recognized certification of its QMS not only for...

ORGANOCAN : UROsphere collaborative project.

Mar 10, 2015

Colorectal cancers and those of the urological sphere (prostate and bladder) are among the five most common cancers. A chronic inflammatory condition predisposes to the appearance of some of these cancers (colon, prostate). Today, the available experimental models poorly simulate the biological reality and function of the body, which makes it particularly difficult to develop new drugs. The objective of the Organocan 2 project is to develop cell models in 3-dimensional (organoid) of colon,...

UROsphere will present its latest scientific developments in preclinical sex health models at the annual meeting of the American Urological Association, to be held in Orlando, Florida, May 16-21, 2014.

May 14, 2014

    Dr Julien Allard will present two moderated posters (session Sexual Function/Dysfunction/Andrology: Basic Research II, room W307) on Monday, May 19th, 08:00-10:00 AM:   Poster 1: Dapoxetine inhibits erectile responses to stimulation of cavernous nerve in rats: a new hypothesis for its effects on ejaculation. Poster 2: Mice with the null leptin receptor as a translational model of type II diabetes-induced erectile dysfunction: in vivo assessment and the effect of sildenafil....

UROsphere presents scientific results at the International Continence Society (ICS) annual meeting (Barcelona, Spain, 26 – 30 August 2013).

Aug 6, 2013

The following scientific results will be presented :   DFL 14817, a new potent and selective TRPM8 antagonist for the treatment of urinary bladder disorders.Palea S1, Guilloteau V1, Brandolini L2, Guardia M1, Rollet K1, Guerard M1, Bianchini G2, Lluel P1, Aramini A2.1. UROsphere, 2. Dompé S.p.A.Podium Session 3 - Basic Science 1: InnovationsWednesday 28th August 2013 - 11:05-12:05.  Modulation of PGE2-augmented micro-contractions by the non-selective ß-adrenoceptor agonist isoprenaline in...

UROsphere will present scientific results at the International Symposium on Prostate, Androgens and Men’s Sexual Health, which will take place in Berlin, Germany from 21 to 23 June 2013.

Jun 21, 2013

        Dr Julien Allard will present the Unmoderated Poster entitled " Mice with null leptin receptor as a translational model of type II diabetes induced erectile dysfunction: in vivo assessment and effect of sildenafil " (final abstract #38). The poster exhibition will be located in meeting room "Postdam I and II" open to all delegates on: Friday 21 June 2013 11:00-19:30 hrs Saturday 22 June 2013 08:00-19:30 hrs   UROsphere's Chief Scientific Officer, Stefano Palea,...

UROsphere present scientific results at EAU 27th annual congress (Paris, France, 24-26 February 2012)

Feb 6, 2012

    It is with pleasure that we will meet you at the booth 1N24, level 1, hall Passy. The following posters will be presented on Sunday, 26 February 2012 from 09h15 to 10h45. Effect of a selective β3-adrenergic agonist (CL-316, 243) on cystometric parameters in conscious spinal cord injured female rats. J.B. Beauval , V. Guilloteau , M. Capellini , A. Naudin , M. Guérard , P. Lluel , S. Palea , P. Rischmann , X. Gamé. Dose-dependent effect of a selective β3 adrenoreceptor agonist...

UROsphere presents scientific results at the 16th World Congress of Basic and Clinical Pharmacology (Copenhagen, Denmark, 17-23 July 2010)

Jun 21, 2010

      The following posters will be presented: Comparison of the effects of AdTx1 and tamsulosin on the increase in intra-urethral and arterial pressures induced by phenylephrine in anesthetized male rats. Effects of duloxetine on bladder and external urethral sphincter in anesthetized female guinea-pigs with intravesical acetic acid.   Stimulation of β3-adrenoceptors inhibits EFS-induced contractions of human isolated urinary bladder. Stimulation of both β2- and...

Urosphere takes parts in MAGenTA, a collaborative research project to develop innovative experimental models and clinical trials dedicated to urogenital diseases.

Apr 29, 2013

The MAGenTA project consists into a collaborative work between four SMEs and two academic institutions. The aim is to develop new and innovative predictive experimental models in order to provide pharmaceutical companies and academic research with better tools that should facilitate the validation of gene candidates and discovery of new molecules. MAGenTA also includes two clinical studies which will enable validation of the effectiveness of two therapeutic molecules for urogenital diseases....

Urosphere unveils its new web site

Mar 9, 2010

UROsphere is pleased to present its new web site that has been redesigned to offer enhanced functionality to better fit with our clients’ needs: Quick access to our assays, models and expertise A restricted area dedicated to our clients Personalized filter by disease area listing pertinent publications Subscribe to our RSS feed to receive our news updates Feel free to contact us with any questions or comments, we will be happy to assist you.

UROsphere and Vectalys selected by the SISMIP for their research programme « Discovery of new targets for prostatic pathologies»

Nov 20, 2007

The 3SI program for Innovation in the Health Sector is a call for innovative projects reserved to SMEs located in Midi-Pyrenees Region. This program is also supported by the Regional Board of OSEO (France's national agency for industrial innovation), the Regional Board for Research and Technology (DRRT), the Cancer-Bio-Health cluster and Midi Pyrénées Innovation (MPI). UROsphere and Vectalys (a company specialized in viral vector production and cell transduction expertises for gene discovery...

Urosphere receives a grant from OSEO Innovation.

Nov 9, 2007

UROsphere announces that OSEO Innovation has awarded a grant over a 2-year period to expand its experimental research platform for early stage drug development. The funding will be used to develop innovative in vivo and in vitro models to offer a wider range of assays for genitourinary pathologies. OSEO innovation (France's national agency for industrial innovation) funds innovative, technology-oriented projects for commercialization in France and abroad.

Urosphere targets genitourinary pathologies (FR)

May 22, 2007

UROsphere cible les pathologies génitourinaires. (Gazette du Laboratoire, Mai 2007) Spécialisée sur le marché de niche des pathologies de l'appareil urinaire, cette jeune entreprise innovante toulousaine développe ses propres molécules et propose des services (études pré-cliniques) à ses clients internationaux.  Article